Non-Vegetarian Ingredient In Herbal Tooth Powder, Delhi HC Issues Notice To Patanjali Ayurveda And Baba Ramdev

New Delhi: Patanjali Ayurved Limited, led by yoga guru Ramdev, is once again under legal scrutiny as the Delhi high court has demanded responses from the Centre, the Food Safety and Standards Authority of India (FSSAI), and the company over a petition alleging misbranding of its “Divya Dant Manjan” dental care product.

The petition, filed by lawyer Yatin Sharma, claims that despite “Divya Dant Manjan” being marketed with a green dot — an indicator of vegetarian status — it actually contains “samudraphen,” a fish-derived compound.

This, according to Sharma, constitutes “misbranding” under the Drugs and Cosmetics Act. Although the law does not mandate specific labelling for drugs as vegetarian or non-vegetarian, the use of the green dot qualifies as “misbranding” under the Drugs and Cosmetics Act, the petitioner’s counsel argued.

Justice Sanjeev Narula issued notice to the Centre, the FSSAI as well as Patanjali, Divya Pharmacy, Yoga guru Ramdev and other related parties on Sharma’s petition.

The petitioner, represented by advocates Swapnil Chaudhary and Prashant Gupta, said the discovery was “distressing” for him and his family, particularly because they adhere to a strict vegetarian diet due to religious beliefs.

“Respondent No. 3 (Patanjali Ayurveda) is selling the same product with a green dot on their official website, indicating that the product is vegetarian in nature, which is contradictory.

“The Petitioner seeks redressal for the profound distress caused by the inadvertent consumption of a non-vegetarian product, emphasizing the importance of upholding religious beliefs and ensuring transparency in product representation,” the petition, filed through lawyers Mohit Solanki and Pulkit Chaudhary, stated.

The matter would be heard next in November.

Related Posts

AB-PMJAY Crackdown: 2,359 Hospitals De-empanelled, 1,200 Suspended for Violating Scheme Guidelines, Nadda Tells Lok Sabha

New Delhi: The Centre has disclosed a significant enforcement action against hospitals found violating the guidelines of the Ayushman Bharat–Pradhan Mantri Jan Arogya Yojana (AB-PMJAY), with 2,359 hospitals de-empanelled, 1,200…

NHS backs delayed‑release treatment for cystinosis

Decision expands options for eligible patients NHS England has recommended delayed‑release mercaptamine bitartrate for routine commissioning for eligible patients aged one year and above with nephropathic cystinosis. The decision provides…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

AB-PMJAY Crackdown: 2,359 Hospitals De-empanelled, 1,200 Suspended for Violating Scheme Guidelines, Nadda Tells Lok Sabha

AB-PMJAY Crackdown: 2,359 Hospitals De-empanelled, 1,200 Suspended for Violating Scheme Guidelines, Nadda Tells Lok Sabha

NHS backs delayed‑release treatment for cystinosis

NHS backs delayed‑release treatment for cystinosis

Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry

Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry